Netrin-1, a missing link between chronic inflammation and tumor progression

Cell Cycle

Volumn 9, Issue 7, 2010, Pages 1253-1262

  Paradisi, Andrea ^a   Mehlen, Patrick ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

Apoptosis; Chronic inflammation; Colorectal tumorigenesis; Dependence receptors; Drug therapy; Gene expression

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NETRIN 1;

APOPTOSIS; CARCINOGENESIS; CELL SURVIVAL; CHRONIC INFLAMMATION; COLORECTAL CANCER; COLORECTAL TUMOR; ENTERITIS; HUMAN; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR PROMOTION; UPREGULATION;

EID: 77953581624     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.7.11072     Document Type: Review

References (114)

1. Serafini T, Kennedy TE, Galko MJ, Mirzayan C, Jessell TM, Tessier-Lavigne M. The netrins define a family of axon outgrowth-promoting proteins homologous to C. elegans UNC-6. Cell 1994; 78:23-6. (Pubitemid 24250806)
2. Serafini T, Colamarino SA, Leonardo ED, Wang H, Beddington R, Skarnes WC, et al. Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system. Cell 1996; 87:1001-14. (Pubitemid 26427984)
3. Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, et al. Deleted in Colorectal Cancer (DCC) encodes a netrin receptor. Cell 1996; 87:175-85. (Pubitemid 26358997)
4. Forcet C, Stein E, Pays L, Corset V, Llambi F, Tessier-Lavigne M, et al. Netrin-1-mediated axon outgrowth requires deleted in colorectal cancer-dependent MAPK activation. Nature 2002; 417:443-7. (Pubitemid 34563536)
5. Ackerman SL, Kozak LP, Przyborski SA, Rund LA, Boyer BB, Knowles BB. The mouse rostral cerebellar malformation gene encodes an UNC-5-like protein. Nature 1997; 386:838-42.
6. Hong K, Hinck L, Nishiyama M, Poo MM, Tessier-Lavigne M, Stein E. A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion. Cell 1999; 97:927-41. (Pubitemid 29375051)
7. Mazelin L, Bernet A, Bonod-Bidaud C, Pays L, Arnaud S, Gespach C, et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature 2004; 431:80-4. (Pubitemid 39215111)
8. Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS, Bredesen DE. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 1998; 395:801-4. (Pubitemid 28485447)
9. Llambi F, Causeret F, Bloch-Gallego E, Mehlen P. Netrin-1 acts as a survival factor via its receptors UNC5H and DCC. EMBO J 2001; 20:2715-22. (Pubitemid 32938556)
10. Rabizadeh S, Oh J, Zhong LT, Yang J, Bitler CM, Butcher LL, et al. Induction of apoptosis by the low-affinity NGF receptor. Science 1993; 261:345-8. (Pubitemid 23281003)
11. Bordeaux MC, Forcet C, Granger L, Corset V, Bidaud C, Billaud M, et al. The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. EMBO J 2000; 19:4056-63. (Pubitemid 30608544)
12. Tauszig-Delamasure S, Yu LY, Cabrera JR, Bouzas-Rodriguez J, Mermet-Bouvier C, Guix C, et al. The TrkC receptor induces apoptosis when the dependence receptor notion meets the neurotrophin paradigm. Proc Natl Acad Sci USA 2007; 104:13361-6. (Pubitemid 47293950)
13. Thibert C, Teillet MA, Lapointe F, Mazelin L, Le Douarin NM, Mehlen P. Inhibition of neuroepithelial patched-induced apoptosis by sonic hedgehog. Science 2003; 301:843-6. (Pubitemid 36962627)
14. Matsunaga E, Tauszig-Delamasure S, Monnier PP, Mueller BK, Strittmatter SM, Mehlen P, et al. RGM and its receptor neogenin regulate neuronal survival. Nat Cell Biol 2004; 6:749-55. (Pubitemid 39144480)
15. Goldschneider D, Mehlen P. Dependence receptors: a new paradign in cell signaling and cancer therapy. Oncogene 2010; in press.
16. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006; 6:449-58.
17. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247:49-56. (Pubitemid 20059936)
18. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-70.
19. Shin SK, Nagasaka T, Jung BH, Matsubara N, Kim WH, Carethers JM, et al. Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer. Gastroenterology 2007; 133:1849-57. (Pubitemid 350180802)
20. Bernet A, Mazelin L, Coissieux MM, Gadot N, Ackerman SL, Scoazec JY, et al. Inactivation of the UNC5C Netrin-1 receptor is associated with tumor progression in colorectal malignancies. Gastroenterology 2007; 133:1840-8. (Pubitemid 350186160)
21. Thiebault K, Mazelin L, Pays L, Llambi F, Joly MO, Scoazec JY, et al. The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. Proc Natl Acad Sci USA 2003; 100:4173-8. (Pubitemid 36418176)
22. Paradisi A, Maisse C, Bernet A, Coissieux MM, Maccarrone M, Scoazec JY, et al. NFkappaB regulates netrin-1 expression and affects the conditional tumor suppressive activity of the netrin-1 receptors. Gastroenterology 2008; 135:1248-57.
23. Paradisi A, Maisse C, Coissieux MM, Gadot N, Lepinasse F, Delloye-Bourgeois C, et al. Netrin-1 upregulation in inflammatory bowel diseases is required for colorectal cancer progression. Proc Natl Acad Sci USA 2009; 106:17146-51.
24. Fitamant J, Guenebeaud C, Coissieux MM, Guix C, Treilleux I, Scoazec JY, et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci USA 2008; 105:4850-5. (Pubitemid 351753835)
25. Delloye-Bourgeois C, Brambilla E, Coissieux MM, Guenebeaud C, Pedeux R, Firlej V, et al. Interference with netrin-1 and tumor cell death in non-small cell lung cancer. J Natl Cancer Inst 2009; 101:237-47.
26. Delloye-Bourgeois C, Fitamant J, Paradisi A, Cappellen D, Douc-Rasy S, Raquin MA, et al. Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med 2009; 206:833-47.
27. Carvalho AL, Chuang A, Jiang WW, Lee J, Begum S, Poeta L, et al. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res 2006; 66:9401-7.
28. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454:428-35.
29. Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol 2009; 9:692-703.
30. Li Q, Withoff S, Verma IM. Inflammation-associated cancer: NFkappaB is the lynchpin. Trends Immunol 2005; 26:318-25.
31. Fukata M, Vamadevan AS, Abreu MT. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol 2009; 21:242-53.
32. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7:131-7.
33. Inohara M, Chamaillard N, McDonald C, Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005; 74:355-83.
34. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? The Lancet 2001; 357:539-45.
35. Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 2009; 8:2005-13.
36. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27:5904-12.
37. Coombes JL, Powrie F. Dendritic cells in intestinal immune regulation. Nat Rev Immunol 2008; 8:435-46. (Pubitemid 351733420)
38. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 2009; 27:313-38.
39. Pasparakis M. Regulation of tissue homeostasis by NFkappaB signalling: implications for inflammatory diseases. Nat Rev Immunol 2009; 9:778-88.
40. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008; 8:411-20. (Pubitemid 351733416)
41. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001; 2:361-7. (Pubitemid 33706348)
42. Zhang SZ, Zhao XH, Zhang DC. Cellular and molecular immunopathogenesis of ulcerative colitis. Cell Mol Immunol 2006; 3:35-40.
43. Abreu MT, Arnold ET, Thomas LS, Gonsky R, Zhou Y, Hu B, et al. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem 2002; 277:20431-7. (Pubitemid 34967339)
44. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68:7010-7. (Pubitemid 32463415)
45. Ortega-Cava CF, Ishihara S, Rumi MA, Kawashima K, Ishimura N, Kazumori H, et al. Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J Immunol 2003; 170:3977-85. (Pubitemid 36428158)
46. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The tolllike receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004; 53:987-92.
47. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-6.
48. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
49. Devlin SM, Yang H, Ippoliti A, Taylor KD, Landers CJ, Su X, et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 2007; 132:576-86.
50. Henckaerts L, Pierik M, Joossens M, Ferrante M, Rutgeerts P, Vermeire S. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 2007; 56:1536-42.
51. Ghosh S, Karin M. Missing Pieces in the NF[kappa]B Puzzle. Cell 2002; 109:81-96.
52. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441:431-6.
53. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5:297-309.
54. Baldwin AS Jr. The NFkappaB and IkappaB proteins: new discoveries and insights. Annu Rev Immunol 1996; 14:649-83.
55. Bonizzi G, Karin M. The two NFkappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25:280-8.
56. Karin M, Greten FR. NFkappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5:749-59. (Pubitemid 41400849)
57. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF[kappa]B activity. Annu Rev Immunol 2000; 18:621-63.
58. Hayden MS, Ghosh S. Signaling to NFkappaB. Genes Dev 2004; 18:2195-224.
59. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al. Activation by IKKalpha of a second, evolutionary conserved, NFkappaB signaling pathway. Science 2001; 293:1495-9. (Pubitemid 32801552)
60. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M. The two faces of IKK and NFkappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemiareperfusion. Nat Med 2003; 9:575-81.
61. Maeda S, Chang L, Li Z-W, Luo J-L, Leffert H, Karin M. IKK[beta] Is Required for Prevention of Apoptosis Mediated by Cell-Bound but Not by Circulating TNF[alpha]. Immunity 2003; 19:725-37.
62. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-71. (Pubitemid 27163860)
63. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NFkappaB activation prevents cell death. Cell 1996; 87:565-76. (Pubitemid 26374329)
64. Lin A, Karin M. NFkappaB in cancer: a marked target. Semin Cancer Biol 2003; 13:107-14.
65. Tsukahara T, Kannagi M, Ohashi T, Kato H, Arai M, Nunez G, et al. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NFkappaB in apoptosis-resistant T-cell transfectants with Tax. J Virol 1999; 73:7981-7.
66. Kreuz S, Siegmund D, Scheurich P, Wajant H. NFkappaB inducers upregulate cFLIP, a cycloheximidesensitive inhibitor of death receptor signaling. Mol Cell Biol 2001; 21:3964-73. (Pubitemid 32476458)
67. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NFkappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001; 21:5299-305. (Pubitemid 32702435)
68. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NFkappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281:1680-3.
69. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor (NF)kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 1998; 188:211-6.
70. Hayden MS, West AP, Ghosh S. NFkappaB and the immune response. Oncogene 2006; 25:6758-80.
71. Ghosh S, Hayden MS. New regulators of NFkappaB in inflammation. Nat Rev Immunol 2008; 8:837-48.
72. Ayabe T, Satchell DP, Wilson CL, Parks WC, Selsted ME, Ouellette AJ. Secretion of microbicidal alphadefensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000; 1:113-8.
73. Ward C, Chilvers ER, Lawson MF, Pryde JG, Fujihara S, Farrow SN, et al. NFkappaB activation is a critical regulator of human granulocyte apoptosis in vitro. J Biol Chem 1999; 274:4309-18.
74. Lai WC, Zhou M, Shankavaram U, Peng G, Wahl LM. Differential regulation of lipopolysaccharideinduced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J Immunol 2003; 170:6244-9.
75. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 2002; 4:157-64.
76. Karin M. The IkappaB kinase - a bridge between inflammation and cancer. Cell Res 2008; 18:334-42.
77. Ellis RD, Goodlad JR, Limb GA, Powell JJ, Thompson RP, Punchard NA. Activation of nuclear factor kappaB in Crohn's disease. Inflamm Res 1998; 47:440-5.
78. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115:357-69.
79. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappaB inflammatory bowel disease. Gut 1998; 42:477-84.
80. Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, et al. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 2006; 116:3195-203.
81. Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 2009; 9:351-69.
82. Karin M, Cao Y, Greten FR, Li ZW. NFkappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2:301-10.
83. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
84. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7.
85. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118:285-96.
86. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 1996; 39:87-92.
87. Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007; 59:1073-83.
88. Grady WM. Making the case for DCC and UNC5C as tumor-suppressor genes in the colon. Gastroenterology 2007; 133:2045-9.
89. Mehlen P, Guenebeaud C. Netrin-1 and its dependence receptors as original targets for cancer therapy. Curr Opin Oncol 2010; 22:46-54.
90. Saccani S, Pantano S, Natoli G. Two waves of nuclear factor kappaB recruitment to target promoters. J Exp Med 2001; 193:1351-9.
91. Kruger RP, Lee J, Li W, Guan KL. Mapping netrin receptor binding reveals domains of Unc5 regulating its tyrosine phosphorylation. J Neurosci 2004; 24:10826-34.
92. Ly NP, Komatsuzaki K, Fraser IP, Tseng AA, Prodhan P, Moore KJ, et al. Netrin-1 inhibits leukocyte migration in vitro and in vivo. Proc Natl Acad Sci USA 2005; 102:14729-34.
93. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, Morote-Garcia JC, et al. Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol 2009.
94. Schubert T, Denk A, Magdefrau U, Kaufmann S, Bastone P, Lowin T, et al. Role of the netrin system of repellent factors on synovial fibroblasts in rheumatoid arthritis and osteoarthritis. Int J Immunopathol Pharmacol 2009; 22:715-22.
95. Wilson BD, Ii M, Park KW, Suli A, Sorensen LK, Larrieu-Lahargue F, et al. Netrins promote developmental and therapeutic angiogenesis. Science 2006; 313:640-4.
96. Castets M, Coissieux MM, Delloye-Bourgeois C, Bernard L, Delcros JG, Bernet A, et al. Inhibition of endothelial cell apoptosis by netrin-1 during angiogenesis. Dev Cell 2009; 16:614-20.
97. Bouvree K, Larrivee B, Lv X, Yuan L, DeLafarge B, Freitas C, et al. Netrin-1 inhibits sprouting angiogenesis in developing avian embryos. Dev Biol 2008; 318:172-83.
98. Larrivee B, Freitas C, Trombe M, Lv X, Delafarge B, Yuan L, et al. Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev 2007; 21:2433-47.
99. Chidlow JH Jr, Shukla D, Grisham MB, Kevil CG. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol 2007; 293:5-18.
100. Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 130:2060-73.
101. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9:653-60.
102. Broide DH, Lawrence T, Doherty T, Cho JY, Miller M, McElwain K, et al. Allergen-induced peribronchial fibrosis and mucus production mediated by IkappaB kinase beta-dependent genes in airway epithelium. Proc Natl Acad Sci USA 2005; 102:17723-8.
103. Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, et al. Interplay of IKK/ NFkappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007; 117:889-901.
104. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, et al. IKKbeta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11:191-8.
105. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKKbeta and NFkappaB. Nat Med 2005; 11:183-90.
106. Pasparakis M, Courtois G, Hafner M, Schmidt-Supprian M, Nenci A, Toksoy A, et al. TNF-mediated inflammatory skin disease in mice with epidermisspecific deletion of IKK2. Nature 2002; 417:861-6.
107. Stratis A, Pasparakis M, Rupec RA, Markur D, Hartmann K, Scharffetter-Kochanek K, et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 2006; 116:2094-104.
108. van Hogerlinden M, Rozell BL, Ahrlund-Richter L, Toftgard R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 1999; 59:3299-303.
109. Lind MH, Rozell B, Wallin RP, van Hogerlinden M, Ljunggren HG, Toftgard R, et al. Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NFkappaB inhibition. Proc Natl Acad Sci USA 2004; 101:4972-7.
110. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11:119-32.
111. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202:275-93.
112. Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004; 4:314-20.
113. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004; 15:280-94.
114. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118:229-41.